​

Whitehawk Therapeutics Stock (NASDAQ:WHWK)

RevenueFinancialsChartTranscripts
Whitehawk Therapeutics by TradingView

Previous Close

$2.70

52W Range

$1.39 - $3.77

50D Avg

$2.46

200D Avg

$2.02

Market Cap

$126.30M

Avg Vol (3M)

$177.49K

Beta

0.69

Div Yield

-

WHWK Company Profile

Whitehawk Therapeutics Inc operates as a clinical-stage biopharmaceutical company. The Company develops precision therapies for genetically-defined cancers.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

40

IPO Date

Aug 01, 2017

Website

WHWK Performance

WHWK Financial Summary

Dec 24Dec 23Dec 22
Revenue$25.98M$24.35M$15.22M
Operating Income$-67.46M$-71.93M$-62.68M
Net Income$-63.69M$-65.77M$-60.51M
EBITDA$-64.63M$-71.76M$-58.80M
Basic EPS$-2.36$-2.44$-2.69
Diluted EPS$-2.36$-2.44$-2.69

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q4 24Mar 19, 25 | 8:30 AM
Q2 24Aug 10, 24 | 8:30 AM
Q1 24May 08, 24 | 8:30 AM

Peer Comparison

TickerCompany
CLNNClene Inc.
ZNTLZentalis Pharmaceuticals, Inc.
TVGNTevogen Bio Holdings Inc.
PLRXPliant Therapeutics, Inc.
ONCYOncolytics Biotech Inc.
IMMXImmix Biopharma, Inc.
MGNXMacroGenics, Inc.
ATOSAtossa Therapeutics, Inc.
CNTXContext Therapeutics Inc.
OVIDOvid Therapeutics Inc.